Elevated serum phosphorus is associated with higher death risk in hemodialysis patients. Previous studies have suggested that both higher serum parathyroid hormone (PTH) level and higher dietary protein intake may contribute to higher serum phosphorus levels. However, it is not well known how these two factors simultaneously contribute to the combined risk of hyperphosphatemia in real patient-care scenarios. We hypothesized that the likelihood of hyperphosphatemia increases across higher serum PTH and higher normalized protein catabolic rate (nPCR) levels, a surrogate of protein intake. Over an 8-year period (July 2001-June 2009), we identified 69,355 maintenance hemodialysis patients with PTH, nPCR, and phosphorus data in a large dialysis provider. Logistic regression models were examined to assess the association between likelihood of hyperphosphatemia (serum phosphorus 45.5 mg/dl) and serum PTH and nPCR increments. Patients were 61±15 years old and included 46% women, 33% blacks, and 57% diabetics. Both higher serum PTH level and higher protein intake were associated with higher risk of hyperphosphatemia in dialysis patients. Compared with patients with PTH level 150-o300 pg/ml and nPCR level 1.0-o1.2 g/kg/day, patients with iPTH4600 pg/ml and nPCR41.2 g/kg/day had a threefold higher risk of hyperphosphatemia (OR: 3.17, 95% CI: 2.69-3.75). Hyperphosphatemia is associated with both higher dietary protein intake and higher serum PTH level in maintenance hemodialysis patients. Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism independent of dietary phosphorus load. Management of hyperphosphatemia should include diligent correction of hyper-parathyroidism while maintaining adequate intake of high protein foods with low phosphorus content.
Elevated serum phosphorus is associated with higher death risk in hemodialysis patients. Previous studies have suggested that both higher serum parathyroid hormone (PTH) level and higher dietary protein intake may contribute to higher serum phosphorus levels. However, it is not well known how these two factors simultaneously contribute to the combined risk of hyperphosphatemia in real patient-care scenarios. We hypothesized that the likelihood of hyperphosphatemia increases across higher serum PTH and higher normalized protein catabolic rate (nPCR) levels, a surrogate of protein intake. Over an 8-year period (July 2001-June 2009), we identified 69,355 maintenance hemodialysis patients with PTH, nPCR, and phosphorus data in a large dialysis provider. Logistic regression models were examined to assess the association between likelihood of hyperphosphatemia (serum phosphorus 45.5 mg/dl) and serum PTH and nPCR increments. Patients were 61±15 years old and included 46% women, 33% blacks, and 57% diabetics. Both higher serum PTH level and higher protein intake were associated with higher risk of hyperphosphatemia in dialysis patients. Compared with patients with PTH level 150-o300 pg/ml and nPCR level 1.0-o1.2 g/kg/day, patients with iPTH4600 pg/ml and nPCR41.2 g/kg/day had a threefold higher risk of hyperphosphatemia (OR: 3.17, 95% CI: 2.69-3.75). Hyperphosphatemia is associated with both higher dietary protein intake and higher serum PTH level in maintenance hemodialysis patients. Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism independent of dietary phosphorus load. Management of hyperphosphatemia should include diligent correction of hyper-parathyroidism while maintaining adequate intake of high protein foods with low phosphorus content. Hyperphosphatemia is a common disorder in individuals with chronic kidney disease (CKD) and results from impaired renal phosphorus clearance and abnormal bone remodeling, in the face of continued intestinal absorption and poor outcomes. [1] [2] [3] [4] [5] [6] [7] [8] The phosphatonins, or hormonal regulators of phosphorus balance, include 1,25-dihydroxyvitamin D, fibroblast growth factor 23 (FGF23) with its cofactor klotho, and parathyroid hormone (PTH). 9 It is noteworthy that phosphorus loading occurs early in CKD stage 3, as evidenced by increased serum levels of FGF23, which precedes rise in PTH or phosphorus levels. 10 Numerous observational studies have associated hyperphosphatemia with increased risk of CKD and mortality both in the general population 1 and in patients with CKD 11, 12 and those on maintenance dialysis. [13] [14] [15] [16] Elevated serum phosphorus likely contributes to cardiovascular disease and death via promotion of vascular calcification. Elevated phosphate drives osteogenic phenotype change 17, 18 and apoptosis 19, 20 pathways leading to mineralization of vascular smooth muscle cells in vitro, and dietary phosphate loading in rodent CKD models increases aortic calcification. 21, 22 Furthermore, hyperphosphatemia may worsen the rate of CKD progression. 23, 24 Because correction and prevention of hyperphosphatemia is a mainstay of CKD management, therapeutic interventions consist of dietary phosphorus restriction, the use of phosphorus binders, and dialysis. As foods high in protein are a major source of dietary phosphorus, it is plausible that increasing protein intake may contribute to hyperphosphatemia. Indeed, decreased protein intake has been correlated with low serum phosphorus and relatively low PTH levels in elderly dialysis patients. 25 Normalized protein nitrogen appearance (nPNA; also referred to as normalized protein catabolic rate (nPCR)) is a commonly used measurement of protein intake in maintenance hemodialysis (MHD) patients. Previous studies have correlated increased dietary phosphate/protein ratio 26 and extremes of nPCR (o0.8 or 41.4 g/kg/day) 27 with increased mortality, although the predictive value of nPCR on serum phosphorus levels appears more complex 28 and has not been well examined.
Control of secondary hyperparathyroidism, another treatment goal in CKD, is often overlooked as an additional therapeutic intervention that impacts serum phosphorus levels. Elevated PTH feeds into abnormal bone turnover such that the skeleton cannot perform its normal function as a reservoir for excess circulating mineral. 9 Results from the OPTIMA trial were recently reported, whereby MHD patients with secondary hyperparathyroidism (PTH levels 300-799 pg/ ml) were randomized to conventional therapy with activated vitamin D and/or phosphate binders versus a cinacalcet-based regimen. 29 The OPTIMA trial found that serum phosphorus control was improved when PTH was effectively lowered, irrespective of treatment strategy. Further evidence for pathological effects of elevated PTH in CKD comes from the studies by Wesseling-Perry et al., 30 whereby intravenous PTH infusion raised serum phosphorus levels in MHD patients but lowered serum phosphorus in healthy volunteers. 30 Given that both nPCR and elevated PTH influence serum phosphorus levels, we propose using both parameters simultaneously as a 'bivariate' predictor of hyperphosphatemia risk. We tested our hypothesis with a large and contemporary cohort of MHD patients.
RESULTS

Baseline characteristics
Over the 5-year period (July 2001-June 2006), 164,789 subjects received dialysis treatment in units owned by DaVita (Figure 1 ). After deleting those patients who did not maintain at least 45 days of thrice-weekly hemodialysis treatment during the base calendar quarter or those who had missing core values (age, dialysis vintage, iPTH, nPCR, and serum phosphorus), 69,355 hemodialysis patients remained. Baseline characteristics of the 69,355 patients stratified by baseline iPTH and nPCR level are presented in Table 1 . Patients with combined higher iPTH and nPCR level tended to be younger males who had longer dialysis duration, less prevalence of diabetes, and other comorbidities: congestive heart failure, atherosclerotic disease, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, and other cardiovascular disease. They also tended to have better nutrition inflammation status with a higher serum albumin and creatinine level and were less likely to be white patients. Figure 2 illustrates the combined (three-dimensional) association of serum iPTH and nPCR with the odds of a serum phosphorus 45.5 g/dl. As shown in Figure 2 , the odds of a serum phosphorus 45.5 g/dl increases linearly with increasing serum iPTH, and there is an increasing trend towards hyperphosphatemia with increments of nPCR. Overall, combined higher serum iPTH level and higher protein intake were associated with higher risk of hyperphosphatemia in dialysis patients. This trend is steeper with increasing nPCR concentrations up to about 1.0 g/kg/day.
To further study the combined predictive effect of nPCR and serum iPTH on hyperphosphatemia, we created 16 groups combining 4 levels of nPCR with 4 levels of serum iPTH. As shown in Figure 3 , using patients with iPTH level 150-o300 pg/ml and nPCR level 1.0-o1.2 g/kg/day as a reference group, patients with iPTH4600 pg/ml and nPCRX1.2 g/kg/day had a threefold higher risk of hyperphosphatemia (OR: 3.17, 95% CI: 2.69-3.75) in fully adjusted models. This figure shows an increasing risk for hyperphosphatemia with increasing levels of iPTH and across increasing levels of serum nPCR. Odds of hyperphosphatemia level per group were similar across unadjusted, case-mix, and case-mix and MICS fully adjusted analyses. Alternative analysis, including modeling hyperphosphatemia across increments of protein intake (nPCR) within subgroups of iPTH levels, resulted in similar trends (see Figure 4) .
In Table 2 , we demonstrate predicted values for serum phosphorus for a white non-diabetic male aged 60 years based on three levels of adjustment: unadjusted, case-mix, case-mix and MICS. This table similarly demonstrates increasing levels of predicted serum phosphorus with increasing levels of iPTH and additionally increasing across increasing levels of nPCR.
DISCUSSION
In this large and contemporary cohort of 69,355 MHD patients, we validated that both nPCR and intact PTH levels were significant and independent predictors of hyperphosphatemia. When considered simultaneously, nPCR o0.8 g/kg/day with PTH levels o150 pg/ml had the lowest odds of associated hyperphosphatemia, whereas nPCRX 1.2 g/kg/day with PTH levels X600 pg/ml correlated with the highest risk of hyperphosphatemia. These correlations remained significant after adjustment for a variety of demographic, comorbid, and inflammation-malnutrition factors. Our data emphasizes the interplay between dietary protein intake, PTH levels, and serum phosphorus. However, the study was not designed to define therapeutic targets for these parameters, and hard clinical outcomes such as mortality were not analyzed. We are by no means advocating for lowend nPCR and PTH levels as management strategies for hyperphosphatemia. Indeed, restricting protein intake has been associated with increased risk of death in CKD, 4, 31 and MHD patients, with nPCR levels 1.0-1.4 g/kg/day conferring best survival. 27 Protein malnutrition with serum albumin levels o3.5 g/dl is a predictor of increased mortality in incident MHD patients. 32 In terms of PTH, the phenomenon of skeletal resistance to PTH in CKD has long been recognized, 33 and several mechanisms have been proposed that are beyond the scope of this paper. Although no randomized trials have validated a target range for PTH levels, observational cohort studies have reported optimal survival in MHD patients when PTH is 150-300 pg/ml. 15, 34 A combination of low serum phosphorus and low PTH levels warrants cautious interpretation, as they may actually reflect protein-energy wasting and inflammation, 15, 35 known predictors of increased mortality. 36 Although the contribution of higher nPCR to increases in serum phosphorus may seem intuitive, adequate protein nutrition is important in MHD patients to avoid increased mortality. 32 Information on the phosphorus/protein ratio in various foods should be a mainstay of low-phosphate diet education; for example, egg whites are an excellent source of protein and have a very low phosphorus-to-protein content. 37 The mechanisms by which secondary hyperparathyroidism may contribute to hyperphosphatemia are less clear. The phosphaturic effects of PTH become irrelevant in the MHD population who are functionally anephric; thus hyperphosphatemia can and is likely to occur in a closed system. Secondary hyperparathyroidism induces hyperphosphatemia largely due to increased phosphorus efflux from bone. In the study by Wesseling-Perry et al., 30 rise in serum phosphorus following PTH infusion in MHD patients was independent of osteodystrophy type (normal/adynamic vs. high turnover) on bone biopsy, suggesting additional extraskeletal effects of elevated PTH on serum phosphorus. Regardless, there is a strong evidence that lowering of serum PTH is associated with lowering of serum phosphorus. Trials using the calcimimetic cinacalcet have attributed serum phosphorus reduction to lowering of PTH. 29, 38 Furthermore, in a Japanese cohort of 15 MHD patients with advanced secondary hyperparathyroidism, serum phosphorus and FGF23 levels declined significantly following total parathyroidectomy. 39 The strength of our study lies in the large number of patients, which made it possible to analyze serum phosphorus associations based on 16 groups (4 nPCR Â 4 iPTH groups) with extensive adjustments for other demographic and nutritional covariates. However, our study has also some limitations. First, data for active vitamin D analogs and phosphate binder treatment were not included in the models. Lack of these data could have biased analysis of iPTH and phosphorus associations. Second, there were no data for residual renal function. Although dialysis duration may be correlated with residual renal function and was adjusted in our model, residual confounding could not be completely excluded. Third, information for comorbid conditions was obtained at the time of initiation of dialysis therapy, 3-22 months before the entry into cohort. Lastly, this is an observational study, hence we cannot determine the direction of effect from detected associations. As discussed above, there is good evidence that PTH elevation can increase serum phosphorus; however, the reverse is also true, whereby dietary phosphate loading has been shown to stimulate PTH secretion in both healthy and CKD rodents. 40, 41 In conclusion, the combination of nPCR and PTH levels served as a robust 'bivariate' predictor of hyperphosphatemia. Secondary hyperparathyroidism is an under-recognized potential mediator of elevated serum phosphorus. Patient education on the phosphorus/protein ratio in foods is warranted when promoting compliance with a low phosphorus diet. Management of hyperphosphatemia may be more effective with diligent treatment of secondary hyperparathyroidism while maintaining adequate protein intake to optimize survival.
METHODS Patients
We retrospectively examined data from all patients receiving HD treatment in one of the DaVita outpatient dialysis facilities during an entry period from 1 July 2001 to 30 June 2006 (i.e., for 20 consecutive calendar quarters). Inclusion criteria were patients age 18 years or older who had been undergoing dialysis for at least 90 days, were being treated with MHD at the time of entry into the cohort and had serum phosphorus, intact PTH (iPTH), and nPCR measurements at the baseline quarter. The study was approved by the Harbor-UCLA Medical Center Institutional Review Board with exemption of the requirement for a written consent form. The study was approved by the Institutional Review Committees of the Los Angeles Biomedical Research Institute at Harbor-UCLA and DaVita Clinical Research. Given the large sample size, anonymity of the patients studied, and nonintrusive nature of the research, requirement for consent was exempted.
Demographic and clinical measures
The creation and analyses of this 5-year, non-concurrent, dynamic cohort of hemodialysis patients have been described previously. 
Statistical methods
Baseline characteristics were summarized as proportions, means ( ± s.d.), or medians (interquartile ranges) as dictated by data type and compared across groups of iPTH and nPCR levels (iPTHo300 with nPCRo1.0, iPTHo300 with nPCRX1.0, iPTH300 with nPCRo1.0 and, iPTH300 with nPCRX1.0), using analysis of variance (or Wilcoxon rank-sum test for non-parametric variables) to determine P-values for difference between groups and linear regression to test for trend or evaluate if there was an increasing or decreasing trend linearly across groups. We examined the possibly non-linear relation between nPCR, iPTH, and the odds ratio (OR) of hyperphosphatemia (phosphorus 45.5 mg/dl) non-parametrically with unadjusted restricted cubic splines 44 . Tests for non-linearity used the likelihood ratio test, comparing the model with only the linear term with the model with the linear and cubic spline terms.
We additionally divided serum iPTH levels a priori into four categories (o150, 150-o300, 300-o600, and X600 pg/ml) and nPCR levels into four categories (o8.0, 8.0-o1.0, 1.0-o1.2, and X1.2 g/kg per day). Patients were then divided into 16 groups according to their iPTH and nPCR levels (4 Â 4 groups). Patients with iPTH level 150-o300 pg/ml and nPCR level 1.0-o1.2 g/kg per day were considered as reference group. ORs of hyperphosphatemia were estimated by fitting multivariable logistic models with three levels of adjustment: (1) Unadjusted model that only included the main predictor variable(s) and calendar quarter of entry; (2) case-mix adjusted models that included age, gender, race/ ethnicity, diabetes mellitus, dialysis vintage, comorbidities, primary insurance, marital status, delivered dialysis dose estimated by singlepool Kt/V, and residual renal function during the entry quarter, that is, urinary urea clearance; and (3) case-mix plus malnutritioninflammation cachexia syndrome (MICS) adjusted models, which included all of the covariates in the case-mix model as well as 10 surrogates of nutritional and inflammatory status: serum albumin, calcium, creatinine, total iron-binding capacity, ferritin, bicarbonate, peripheral white blood cell count, lymphocyte percentage, hemoglobin and body mass index. Linear regression models were used to create predicted values of serum phosphorus with given levels of nPCR and serum iPTH using the same three levels of adjustment. Missing covariate data of continuous and binary variables were imputed by multiple imputation methods and a category of missing covariate data was created for each categorical variable with more than two categories. Analyses were carried out with SAS version 9.3 (SAS Institute, Cary, NC) and Stata version 10.1 (Stata Corporation, College Station, TX).
